menu
    • menu
    [{"orgOrder":0,"company":"Beactica","sponsor":"Oscotec","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"LSD1 allosteric","graph1":"Oncology","graph2":"Discovery","graph3":"Beactica","amount2":0.02,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"","sponsorNew":"Beactica \/ Oscotec","highestDevelopmentStatusID":"2","companyTruncated":"Beactica \/ Oscotec"},{"orgOrder":0,"company":"Beactica","sponsor":"Dong-A ST Co., Ltd.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Termination","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Beactica","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Beactica \/ Dong-A ST","highestDevelopmentStatusID":"2","companyTruncated":"Beactica \/ Dong-A ST"},{"orgOrder":0,"company":"Beactica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"BEA-17","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Beactica","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Beactica \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Beactica \/ Not Applicable"},{"orgOrder":0,"company":"Beactica","sponsor":"Oscotec","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Termination","leadProduct":"BEA-17","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Beactica","amount2":0.17999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.17999999999999999,"dosageForm":"","sponsorNew":"Beactica \/ Oscotec","highestDevelopmentStatusID":"4","companyTruncated":"Beactica \/ Oscotec"},{"orgOrder":0,"company":"Beactica","sponsor":"National Center for Advancing Translational Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"YAP\u2013TEAD","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Beactica","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Beactica \/ National Center for Advancing Translational Sciences","highestDevelopmentStatusID":"4","companyTruncated":"Beactica \/ National Center for Advancing Translational Sciences"}]

    Find Clinical Drug Pipeline Developments & Deals by Beactica

    Menu

    Beactica

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Beactica

                            Sweden arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Beactica

                            Sweden arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : YAP–TEAD

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : National Center for Advancing Translational Sciences

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Beactica Therapeutics Announces Collaboration with the National Center for Advancing Translational Sciences

                            Details : Under the collaboration, NCATS will gain access to proprietary novel proteolysis-targeting degraders of TEAD, including YAP–TEAD, from Beactica to evaluate their efficacy in disease-relevant preclinical models for treatment of cancer.

                            Brand Name : YAP–TEAD

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            September 26, 2023

                            Lead Product(s) : YAP–TEAD

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : National Center for Advancing Translational Sciences

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Beactica

                            Sweden arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Beactica

                            Sweden arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BEA-17

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Oscotec

                            Deal Size : $178.0 million

                            Deal Type : Termination

                            DEALS_DEV arrow-down

                            Beactica Therapeutics and Oscotec Mutually Agree to Conclude Oncology Collaboration

                            Details : Under the agreement, Beactica Therapeutics will retain full exclusive global rights for further development and commercialization of the LSD1 programme, including BEA-17, a first-in-class small molecule targeted degrader of the epigenetic enzyme LSD1 and...

                            Brand Name : BEA-17

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            April 04, 2023

                            Lead Product(s) : BEA-17

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Oscotec

                            Deal Size : $178.0 million

                            Deal Type : Termination

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Beactica

                            Sweden arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Beactica

                            Sweden arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BEA-17

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Beactica Therapeutics Receives FDA Orphan Drug Designation for BEA-17 For the Treatment of Glioblastoma

                            Details : BEA-17 is a first-in-class small molecule targeted degrader (non-PROTAC) of the epigenetic enzyme LSD1 and its co-factor CoREST. The compound has shown promising preclinical in vivo potentiation of immune-modulating treatments in several cancer forms.

                            Brand Name : BEA-17

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 01, 2023

                            Lead Product(s) : BEA-17

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Beactica

                            Sweden arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Beactica

                            Sweden arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Sponsor : Dong-A ST Co., Ltd.

                            Deal Size : Undisclosed

                            Deal Type : Termination

                            DEALS_DEV arrow-down

                            Dong-A ST and Beactica Therapeutics Mutually Agree to Conclude Oncology Collaboration

                            Details : As part of the termination, both Dong-A ST and Beactica Therapeutics will gain exclusive global rights for further development and commercialization for different compounds series developed during the collaboration.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            September 06, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Sponsor : Dong-A ST Co., Ltd.

                            Deal Size : Undisclosed

                            Deal Type : Termination

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Beactica

                            Sweden arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Beactica

                            Sweden arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Sponsor : Oscotec

                            Deal Size : $17.8 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Oscotec and Beactica Therapeutics Announce License and Collaboration Agreement to Develop New Cancer Drug

                            Details : Under the terms of the agreement, Oscotec is entitled to gain exclusive global rights for further development and commercialization of Beactica's programme.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            March 02, 2021

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Sponsor : Oscotec

                            Deal Size : $17.8 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth